Literature DB >> 10954575

Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element.

R P Haberman1, T J McCown, R J Samulski.   

Abstract

Adeno-associated virus (AAV) type 2 vectors transfer stable, long-term gene expression to diverse cell types in vivo. Many gene therapy applications require the control of long-term transgene expression, and AAV vectors, similar to other gene transfer systems, are being evaluated for delivery of regulated gene expression cassettes. Previously, we (R. P. Haberman, T. J. McCown, and R. J. Samulski, Gene Ther. 5:1604-1611, 1998) demonstrated the use of the tetracycline-responsive system for long-term regulated expression in rat brains. In that study, we also observed residual expression in the "off" state both in vitro and in vivo, suggesting that the human cytomegalovirus (CMV) major immediate-early minimal promoter or other cis-acting elements (AAV terminal repeats [TR]) were contributing to this activity. In the present study, we identify that the AAV TR, minus the tetracycline-responsive minimal CMV promoter, will initiate mRNA expression from vector templates. Using deletion analysis and specific PCR-derived TR reporter gene templates, we mapped this activity to a 37-nucleotide stretch in the A/D elements of the TR. Although the mRNA derived from the TR is generated from a non-TATA box element, the use of mutant templates failed to identify function of canonical initiator sequences as previously described. Finally, we demonstrated the presence of green fluorescent protein expression both in vitro and in vivo in brain by using recombinant virus carrying only the TR element. Since the AAV terminal repeat is a necessary component of all recombinant AAV vectors, this TR transcriptional activity may interfere with all regulated expression cassettes and may be a problem in the development of novel TR split gene vectors currently being considered for genes too large to be packaged.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954575      PMCID: PMC116385          DOI: 10.1128/jvi.74.18.8732-8739.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Targeting DNA secondary structures.

Authors:  R M Wadkins
Journal:  Curr Med Chem       Date:  2000-01       Impact factor: 4.530

2.  CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector.

Authors:  R C Rubenstein; U McVeigh; T R Flotte; W B Guggino; P L Zeitlin
Journal:  Gene Ther       Date:  1997-05       Impact factor: 5.250

3.  Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter.

Authors:  C J Ring; J D Harris; H C Hurst; N R Lemoine
Journal:  Gene Ther       Date:  1996-12       Impact factor: 5.250

4.  Modulation of the specificity and activity of a cellular promoter in an adenoviral vector.

Authors:  Q Shi; Y Wang; R Worton
Journal:  Hum Gene Ther       Date:  1997-03-01       Impact factor: 5.695

Review 5.  AAV vectors: is clinical success on the horizon?

Authors:  P E Monahan; R J Samulski
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

6.  A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells.

Authors:  S Freundlieb; C Schirra-Müller; H Bujard
Journal:  J Gene Med       Date:  1999 Jan-Feb       Impact factor: 4.565

7.  Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats.

Authors:  X S Wang; K Qing; S Ponnazhagan; A Srivastava
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle.

Authors:  X Xiao; W Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.

Authors:  C K Conrad; S S Allen; S A Afione; T C Reynolds; S E Beck; M Fee-Maki; X Barrazza-Ortiz; R Adams; F B Askin; B J Carter; W B Guggino; T R Flotte
Journal:  Gene Ther       Date:  1996-08       Impact factor: 5.250

10.  Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.

Authors:  A Kistner; M Gossen; F Zimmermann; J Jerecic; C Ullmer; H Lübbert; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

View more
  40 in total

1.  Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses.

Authors:  Jianming Qiu; Ramnath Nayak; Gregory E Tullis; David J Pintel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 3.  AAV: An Overview of Unanswered Questions.

Authors:  Kenneth I Berns; Nicholas Muzyczka
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

Review 4.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 5.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 6.  Strategies for targeting primate neural circuits with viral vectors.

Authors:  Yasmine El-Shamayleh; Amy M Ni; Gregory D Horwitz
Journal:  J Neurophysiol       Date:  2016-04-06       Impact factor: 2.714

7.  Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.

Authors:  Grant J Logan; Allison P Dane; Claus V Hallwirth; Christine M Smyth; Emilie E Wilkie; Anais K Amaya; Erhua Zhu; Neeta Khandekar; Samantha L Ginn; Sophia H Y Liao; Sharon C Cunningham; Natsuki Sasaki; Martí Cabanes-Creus; Patrick P L Tam; David W Russell; Leszek Lisowski; Ian E Alexander
Journal:  Nat Genet       Date:  2017-06-19       Impact factor: 38.330

8.  Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Authors:  Joshua C Grieger; Richard J Samulski
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  Adeno-Associated Virus Serotype-Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression.

Authors:  Lauriel F Earley; Laura M Conatser; Victoria M Lue; Amanda L Dobbins; Chengwen Li; Matthew L Hirsch; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2020-02       Impact factor: 5.695

10.  Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form.

Authors:  Marie-Claude Geoffroy; Alberto L Epstein; Estelle Toublanc; Philippe Moullier; Anna Salvetti
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.